Search

Your search keyword '"Morrow, C"' showing total 1,419 results
Start Over Author "Morrow, C"
1,419 results on '"Morrow, C"'

1. Money Management for Young Adults with Autism. Autism at-a-Glance

Author

University of North Carolina at Chapel Hill, Center on Secondary Education for Students with Autism Spectrum Disorder (CSESA), Morrow, C., and Dees, B.

Abstract

Like many young adults transitioning into the next phase of their life, young adults with autism desire increased independence and autonomy and want to feel confident in their ability to succeed. However, young adults with autism are often less financially independent compared to other youth, including other peers with special health care needs. Financial literacy is often not taught in high schools, with only 21 US states requiring students to take a course that integrates personal finance. This results in many young adults having limited knowledge of money management. Transition services for high school students with ASD often lack a personal finance component as well. This "Autism at-a-Glance" is designed to support practitioners and family members in developing and promoting money management skills for young adults on the autism spectrum.

Published
2020

2. Promoting Literacy Outside the School Environment. Autism at-a-Glance

Author

University of North Carolina at Chapel Hill, Center on Secondary Education for Students with Autism Spectrum Disorder (CSESA), Morrow, C., and McIntyre, N.

Abstract

"Autism at-a-Glance" is a series of practitioner and family-friendly documents created by the Center on Secondary Education for Students with ASD (CSESA) designed for high school staff members supporting students on the autism spectrum, as well as family members of adolescents with ASD. The purpose of the "Autism at-a-Glance" series is to provide a current summary of topics relevant to high school students with ASD as well as practical tips and resources for school and community personnel and family members. This "Autism at-a-Glance" was designed to support parents and other family members in supporting adolescents on the autism spectrum as they develop their literacy at home and in the community.

Published
2019

16. Recombinant Viruses as Vectors for Mucosal Immunity

Author

Morrow, C. D., Novak, M. J., Ansardi, D. C., Porter, D. C., Moldoveanu, Z., Compans, R. W., editor, Cooper, M., editor, Hogle, J. M., editor, Ito, Y., editor, Koprowski, H., editor, Melchers, F., editor, Oldstone, M., editor, Olsnes, S., editor, Potter, M., editor, Saedler, H., editor, Vogt, P. K., editor, Wagner, H., editor, Kraehenbuhl, Jean-Pierre, editor, and Neutra, Marian R., editor

Published
1999
Full Text
View/download PDF

31. RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response

Author

Penn-Nicholson, A, Mbandi, SK, Thompson, E, Mendelsohn, SC, Suliman, S, Chegou, NN, Malherbe, ST, Darboe, F, Erasmus, M, Hanekom, WA, Bilek, N, Fisher, M, Kaufmann, SHE, Winter, J, Murphy, M, Wood, R, Morrow, C, Van Rhijn, I, Moody, B, Murray, M, Andrade, BB, Sterling, TR, Sutherland, J, Naidoo, K, Padayatchi, N, Walzl, G, Hatherill, M, Zak, D, Scriba, TJ, Kafaar, F, Workman, L, Mulenga, H, Hughes, EJ, Xasa, O, Veldsman, A, Cloete, Y, Abrahams, D, Moyo, S, Gelderbloem, S, Tameris, M, Geldenhuys, H, Ehrlich, R, Verver, S, Geiter, L, Black, GF, van der Spuy, G, Stanley, K, Kriel, M, Du Plessis, N, Nene, N, Roberts, T, Kleynhans, L, Gutschmidt, A, Smith, B, Loxton, AG, Tromp, G, Tabb, D, Ottenhoff, THM, Klein, MR, Haks, MC, Franken, KLMC, Geluk, A, van Meijgaarden, KE, Joosten, SA, Boom, WH, Thiel, B, Mayanja-Kizza, H, Joloba, M, Zalwango, S, Nsereko, M, Okwera, B, Kisingo, H, Parida, SK, Golinski, R, Maertzdorf, J, Weiner, J, Jacobson, M, Dockrell, H, Smith, S, Gorak-Stolinska, P, Hur, YG, Lalor, M, Lee, JS, Crampin, AC, French, N, Ngwira, B, Ben-Smith, A, Watkins, K, Ambrose, L, Simukonda, F, Mvula, H, Chilongo, F, Saul, J, Branson, K, Mahomed, H, Downing, K, The Adolescent Cohort Study team, The GC6-74 Consortium, The SATVI Clinical and Laboratory Team, The ScreenTB Consortium, The AE-TBC Consortium, The RePORT Brazil Team, Peruvian Household Contacts Cohort Team, The CAPRISA IMPRESS team, APH - Methodology, APH - Global Health, AII - Amsterdam institute for Infection and Immunity, Global Health, AII - Infectious diseases, and Translational Immunology Groningen (TRIGR)

Subjects
0301 basic medicine, Oncology, Male, GC6-74 Consortium, AE-TBC Consortium, lcsh:Medicine, HIV Infections, Disease, Biomarkers/metabolism, Lung/diagnostic imaging, ScreenTB Consortium, Cohort Studies, Prognostic markers, 0302 clinical medicine, Immunopathology, Peruvian Household Contacts Cohort Team, CAPRISA IMPRESS team, 030212 general & internal medicine, lcsh:Science, Lung, Subclinical infection, screening and diagnosis, RNA, Bacterial/metabolism, Multidisciplinary, Bacterial/metabolism, Bacterial, Prognosis, Tuberculosis/complications, RNA, Bacterial, Detection, Infectious Diseases, Mycobacterium tuberculosis/genetics, Area Under Curve, Cohort, Biomarker (medicine), HIV/AIDS, Female, Adolescent Cohort Study team, Infection, Cohort study, 4.2 Evaluation of markers and technologies, RePORT Brazil Team, medicine.medical_specialty, Tuberculosis, Adolescent, Point-of-Care Systems, HIV Infections/complications, Real-Time Polymerase Chain Reaction/methods, Real-Time Polymerase Chain Reaction, Sensitivity and Specificity, Article, 03 medical and health sciences, Rare Diseases, Tuberculosis diagnosis, Clinical Research, Internal medicine, medicine, Humans, business.industry, SATVI Clinical and Laboratory Team, Prevention, lcsh:R, Diagnostic markers, Mycobacterium tuberculosis, medicine.disease, 4.1 Discovery and preclinical testing of markers and technologies, 030104 developmental biology, Good Health and Well Being, ROC Curve, Positron-Emission Tomography, RNA, lcsh:Q, business, Biomarkers
Abstract

Improved tuberculosis diagnostics and tools for monitoring treatment response are urgently needed. We developed a robust and simple, PCR-based host-blood transcriptomic signature, RISK6, for multiple applications: identifying individuals at risk of incident disease, as a screening test for subclinical or clinical tuberculosis, and for monitoring tuberculosis treatment. RISK6 utility was validated by blind prediction using quantitative real-time (qRT) PCR in seven independent cohorts. Prognostic performance significantly exceeded that of previous signatures discovered in the same cohort. Performance for diagnosing subclinical and clinical disease in HIV-uninfected and HIV-infected persons, assessed by area under the receiver-operating characteristic curve, exceeded 85%. As a screening test for tuberculosis, the sensitivity at 90% specificity met or approached the benchmarks set out in World Health Organization target product profiles for non-sputum-based tests. RISK6 scores correlated with lung immunopathology activity, measured by positron emission tomography, and tracked treatment response, demonstrating utility as treatment response biomarker, while predicting treatment failure prior to treatment initiation. Performance of the test in capillary blood samples collected by finger-prick was noninferior to venous blood collected in PAXgene tubes. These results support incorporation of RISK6 into rapid, capillary blood-based point-of-care PCR devices for prospective assessment in field studies.

Published
2020

41. In vitro release of lymphotoxin by spleen cells from C3H/HEJ and C57BL/6 mice infected with Trypanosoma cruzi.

Author

Krassner, SM, Granger, B, Morrow, C, and Granger, G

Subjects
Spleen, Lymphocytes, Animals, Mice, Inbred A, Mice, Inbred C3H, Mice, Inbred C57BL, Mice, Chagas Disease, Phytohemagglutinins, Lymphocyte Activation, Time Factors, Lymphotoxin-alpha, Inbred A, Inbred C3H, Inbred C57BL, Tropical Medicine, Medical and Health Sciences
Abstract

Lectin (PHA-P) activated nonadherent spleen cells from uninfected inbred strains of mice known to exhibit high parasitemias when infected with Trypanosoma cruzi (A/J and C3H/HeJ), released in vitro significantly less lymphotoxin (LT) than did a mouse strain (C57BL/6) known to exhibit low parasitemia when infected with T. cruzi. The capacity of mice to release LT in vitro changed upon infection with T. cruzi. Cells from infected C57BL/6 mice released LT levels well above that from uninfected C57BL/6 animals within 4 days after initial infection, and their capacity to release LT remained high even after the parasites were not detectable in the blood. Cells from infected C3H/HeJ mice were not able to respond as rapidly as those fom C57BL/6 animals; however, they were able to release LT at the same levels as the infected C57BL/6 by day 18. The parasitemia induced by Trypanosoma cruzi in C3H/HeJ and C57BL/6 mice was compared with the in vitro ability of their spleen cells to spontaneously release LT. Spontaneous release of LT was significantly higher by spleen cells from infected C57BL/6 mice than by cells from infected C3H/HeJ mice. The kinetics of natural LT release differed from that of mitogen-(PHA-P)-stimulated LT release; LT activity peaked at 3-6 hours of incubation in the former and then declined whereas LT activity in the latter reached a plateau after 3 hours of incubation and did not decline for at least 18 hours in the presence of the inducer. Supernatants from infected C57BL/6 splenocytes, when concentrated 5x by ultrafiltration, significantly inhibited both blood stream trypomastigote motility in vitro and their infectivity (by 98%) for WI38 human embryonic lung cell cultures. Similar preparations from C3H/HeJ splenocytes only slightly inhibited bloodstream trypomastigote motility and delayed, but did not prevent, infection of WI38 cells. No agglutination of immobilized parasites was noted. Splenocyte supernatants did not affect culture epimastigote motility or growth. This is the first report of direct action by lymphokine-containing supernatants against T. cruzi bloodstream trypomastigotes.

Published
1982

46. Predicting Virological Response to HIV Treatment Over Time: A Tool for Settings With Different Definitions of Virological Response

Author

Revell, AD, Wang, DC, Reiss, P, van Sighem, AI, Montaner, JSG, Larder, BA, Harrigan, R, de Wit, TR, Hamers, R, Sigaloff, K, Agan, B, Marconi, V, Wegner, S, Sugiura, W, Zazzi, M, Kaiser, R, Schuelter, E, Streinu-Cercel, A, Bals, M, Alvarez-Uria, G, de Oliveira, T, Lazzari, E, Gazzard, B, Nelson, M, Pozniak, A, Mandalia, S, Smith, C, Ruiz, L, Clotet, B, Staszewski, S, Lane, HC, Julia, A, Metcalf, Rehm, CA, Perez-Elias, MJ, Vella, S, Dettorre, G, Carr, A, Norris, R, Hesse, K, Vlahakis, E, Tempelman, H, Barth, R, Wood, R, Morrow, C, Cogill, D, Hoffmann, C, Ene, L, Dragovic, G, Diaz, R, Sucupira, C, Sued, O, Cesar, C, Madero, JS, Balakrishnan, P, Saravanan, S, Cooper, D, Torti, C, Baxter, J, Monno, L, Gatell, J, Picchio, G, deBethune, MP, Emery, S, Khabo, P, and Ledwaba, L

Subjects
machine learning, antiretroviral therapy, HIV/AIDS, treatment response, data mining, viral load
Abstract

Objective: Definitions of virological response vary from

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results